Depocyt

Leukemia, Leukemia, Leukemia, Myelocytic, Acute + 8 more

Treatment

2 FDA approvals

20 Active Studies for Depocyt

What is Depocyt

Cytarabine

The Generic name of this drug

Treatment Summary

Cytarabine is a medication used to treat leukemia, a type of cancer that affects white blood cells. It blocks the production of DNA in cancer cells and is effective during the S phase of the cell cycle. Cytarabine also has properties that can help reduce the symptoms of viruses and suppress the immune system.

Cytarabine

is the brand name

image of different drug pills on a surface

Depocyt Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Cytarabine

Cytarabine

1990

31

Approved as Treatment by the FDA

Cytarabine, otherwise called Cytarabine, is approved by the FDA for 2 uses including Non-Hodgkin's Lymphoma (NHL) and Non-Hodgkin's Lymphoma .

Non-Hodgkin's Lymphoma (NHL)

Used to treat Non-Hodgkin's Lymphoma (NHL) in combination with Carmustine

Non-Hodgkin's Lymphoma

Used to treat Non-Hodgkin's Lymphoma (NHL) in combination with Carmustine

Effectiveness

How Depocyt Affects Patients

Cytarabine is an antineoplastic drug used to treat certain types of leukemia. It works by disguising itself as a building block of DNA, in order to prevent the formation of new cells. Once it is taken in and metabolized, the active form of the drug damages DNA by blocking the creation of new cells and interfering with the repair of existing cells. Cytarabine is most effective when targeting cells in the S phase of the cell cycle.

How Depocyt works in the body

Cytarabine targets rapidly dividing cells, like cancerous ones. It works by damaging the DNA of these cells, making it difficult for them to reproduce. It also stops cells from progressing from the G1 to S-phase of the cell cycle. The exact way it does this is not fully known, but it may interfere with the DNA polymerase process. Cytarabine has also been found in both DNA and RNA.

When to interrupt dosage

The measure of Depocyt is contingent upon the identified condition, including Leptomeningeal Metastases, Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia. The amount of dosage is contingent upon the technique of application (e.g. Intravenous or Solution - Intrathecal; Intravenous; Subcutaneous) as depicted in the accompanying table.

Condition

Dosage

Administration

Acute Promyelocytic Leukemia

, 100.0 mg/mL, 20.0 mg/mL, 200.0 mg/mL, 100.0 mg, 500.0 mg, 2000.0 mg, 1000.0 mg, 50.0 mg, 50.0 mg/mL, 10.0 mg/mL, 5.0 mg/mL

, Injection, Injection - Intravenous; Subcutaneous, Intrathecal; Intravenous; Subcutaneous, Injection - Intrathecal; Intravenous; Subcutaneous, Intravenous; Subcutaneous, Powder, for solution, Powder, for solution - Intrathecal; Intravenous; Subcutaneous, Solution, Solution - Intrathecal; Intravenous; Subcutaneous, Liquid, Liquid - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intrathecal; Intravenous; Subcutaneous, Intrathecal, Injection, suspension, Injection, suspension - Intrathecal, Injection, solution - Intravenous, Intravenous, Injection, solution - Intravenous; Subcutaneous, Suspension, Suspension - Intrathecal, Injection, lipid complex, Injection, lipid complex - Intrathecal, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intrathecal; Intravenous; Subcutaneous, Powder, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder - Intravenous

Leukemia

, 100.0 mg/mL, 20.0 mg/mL, 200.0 mg/mL, 100.0 mg, 500.0 mg, 2000.0 mg, 1000.0 mg, 50.0 mg, 50.0 mg/mL, 10.0 mg/mL, 5.0 mg/mL

, Injection, Injection - Intravenous; Subcutaneous, Intrathecal; Intravenous; Subcutaneous, Injection - Intrathecal; Intravenous; Subcutaneous, Intravenous; Subcutaneous, Powder, for solution, Powder, for solution - Intrathecal; Intravenous; Subcutaneous, Solution, Solution - Intrathecal; Intravenous; Subcutaneous, Liquid, Liquid - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intrathecal; Intravenous; Subcutaneous, Intrathecal, Injection, suspension, Injection, suspension - Intrathecal, Injection, solution - Intravenous, Intravenous, Injection, solution - Intravenous; Subcutaneous, Suspension, Suspension - Intrathecal, Injection, lipid complex, Injection, lipid complex - Intrathecal, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intrathecal; Intravenous; Subcutaneous, Powder, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder - Intravenous

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

, 100.0 mg/mL, 20.0 mg/mL, 200.0 mg/mL, 100.0 mg, 500.0 mg, 2000.0 mg, 1000.0 mg, 50.0 mg, 50.0 mg/mL, 10.0 mg/mL, 5.0 mg/mL

, Injection, Injection - Intravenous; Subcutaneous, Intrathecal; Intravenous; Subcutaneous, Injection - Intrathecal; Intravenous; Subcutaneous, Intravenous; Subcutaneous, Powder, for solution, Powder, for solution - Intrathecal; Intravenous; Subcutaneous, Solution, Solution - Intrathecal; Intravenous; Subcutaneous, Liquid, Liquid - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intrathecal; Intravenous; Subcutaneous, Intrathecal, Injection, suspension, Injection, suspension - Intrathecal, Injection, solution - Intravenous, Intravenous, Injection, solution - Intravenous; Subcutaneous, Suspension, Suspension - Intrathecal, Injection, lipid complex, Injection, lipid complex - Intrathecal, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intrathecal; Intravenous; Subcutaneous, Powder, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder - Intravenous

Neoplasm Metastasis

, 100.0 mg/mL, 20.0 mg/mL, 200.0 mg/mL, 100.0 mg, 500.0 mg, 2000.0 mg, 1000.0 mg, 50.0 mg, 50.0 mg/mL, 10.0 mg/mL, 5.0 mg/mL

, Injection, Injection - Intravenous; Subcutaneous, Intrathecal; Intravenous; Subcutaneous, Injection - Intrathecal; Intravenous; Subcutaneous, Intravenous; Subcutaneous, Powder, for solution, Powder, for solution - Intrathecal; Intravenous; Subcutaneous, Solution, Solution - Intrathecal; Intravenous; Subcutaneous, Liquid, Liquid - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intrathecal; Intravenous; Subcutaneous, Intrathecal, Injection, suspension, Injection, suspension - Intrathecal, Injection, solution - Intravenous, Intravenous, Injection, solution - Intravenous; Subcutaneous, Suspension, Suspension - Intrathecal, Injection, lipid complex, Injection, lipid complex - Intrathecal, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intrathecal; Intravenous; Subcutaneous, Powder, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder - Intravenous

Non-Hodgkin's Lymphoma

, 100.0 mg/mL, 20.0 mg/mL, 200.0 mg/mL, 100.0 mg, 500.0 mg, 2000.0 mg, 1000.0 mg, 50.0 mg, 50.0 mg/mL, 10.0 mg/mL, 5.0 mg/mL

, Injection, Injection - Intravenous; Subcutaneous, Intrathecal; Intravenous; Subcutaneous, Injection - Intrathecal; Intravenous; Subcutaneous, Intravenous; Subcutaneous, Powder, for solution, Powder, for solution - Intrathecal; Intravenous; Subcutaneous, Solution, Solution - Intrathecal; Intravenous; Subcutaneous, Liquid, Liquid - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intrathecal; Intravenous; Subcutaneous, Intrathecal, Injection, suspension, Injection, suspension - Intrathecal, Injection, solution - Intravenous, Intravenous, Injection, solution - Intravenous; Subcutaneous, Suspension, Suspension - Intrathecal, Injection, lipid complex, Injection, lipid complex - Intrathecal, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intrathecal; Intravenous; Subcutaneous, Powder, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder - Intravenous

Newly Diagnosed

, 100.0 mg/mL, 20.0 mg/mL, 200.0 mg/mL, 100.0 mg, 500.0 mg, 2000.0 mg, 1000.0 mg, 50.0 mg, 50.0 mg/mL, 10.0 mg/mL, 5.0 mg/mL

, Injection, Injection - Intravenous; Subcutaneous, Intrathecal; Intravenous; Subcutaneous, Injection - Intrathecal; Intravenous; Subcutaneous, Intravenous; Subcutaneous, Powder, for solution, Powder, for solution - Intrathecal; Intravenous; Subcutaneous, Solution, Solution - Intrathecal; Intravenous; Subcutaneous, Liquid, Liquid - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intrathecal; Intravenous; Subcutaneous, Intrathecal, Injection, suspension, Injection, suspension - Intrathecal, Injection, solution - Intravenous, Intravenous, Injection, solution - Intravenous; Subcutaneous, Suspension, Suspension - Intrathecal, Injection, lipid complex, Injection, lipid complex - Intrathecal, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intrathecal; Intravenous; Subcutaneous, Powder, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder - Intravenous

Acute Lymphoblastic Leukemia

, 100.0 mg/mL, 20.0 mg/mL, 200.0 mg/mL, 100.0 mg, 500.0 mg, 2000.0 mg, 1000.0 mg, 50.0 mg, 50.0 mg/mL, 10.0 mg/mL, 5.0 mg/mL

, Injection, Injection - Intravenous; Subcutaneous, Intrathecal; Intravenous; Subcutaneous, Injection - Intrathecal; Intravenous; Subcutaneous, Intravenous; Subcutaneous, Powder, for solution, Powder, for solution - Intrathecal; Intravenous; Subcutaneous, Solution, Solution - Intrathecal; Intravenous; Subcutaneous, Liquid, Liquid - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intrathecal; Intravenous; Subcutaneous, Intrathecal, Injection, suspension, Injection, suspension - Intrathecal, Injection, solution - Intravenous, Intravenous, Injection, solution - Intravenous; Subcutaneous, Suspension, Suspension - Intrathecal, Injection, lipid complex, Injection, lipid complex - Intrathecal, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intrathecal; Intravenous; Subcutaneous, Powder, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder - Intravenous

Leukemia, Myelocytic, Acute

, 100.0 mg/mL, 20.0 mg/mL, 200.0 mg/mL, 100.0 mg, 500.0 mg, 2000.0 mg, 1000.0 mg, 50.0 mg, 50.0 mg/mL, 10.0 mg/mL, 5.0 mg/mL

, Injection, Injection - Intravenous; Subcutaneous, Intrathecal; Intravenous; Subcutaneous, Injection - Intrathecal; Intravenous; Subcutaneous, Intravenous; Subcutaneous, Powder, for solution, Powder, for solution - Intrathecal; Intravenous; Subcutaneous, Solution, Solution - Intrathecal; Intravenous; Subcutaneous, Liquid, Liquid - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intrathecal; Intravenous; Subcutaneous, Intrathecal, Injection, suspension, Injection, suspension - Intrathecal, Injection, solution - Intravenous, Intravenous, Injection, solution - Intravenous; Subcutaneous, Suspension, Suspension - Intrathecal, Injection, lipid complex, Injection, lipid complex - Intrathecal, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intrathecal; Intravenous; Subcutaneous, Powder, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder - Intravenous

Leukemia

, 100.0 mg/mL, 20.0 mg/mL, 200.0 mg/mL, 100.0 mg, 500.0 mg, 2000.0 mg, 1000.0 mg, 50.0 mg, 50.0 mg/mL, 10.0 mg/mL, 5.0 mg/mL

, Injection, Injection - Intravenous; Subcutaneous, Intrathecal; Intravenous; Subcutaneous, Injection - Intrathecal; Intravenous; Subcutaneous, Intravenous; Subcutaneous, Powder, for solution, Powder, for solution - Intrathecal; Intravenous; Subcutaneous, Solution, Solution - Intrathecal; Intravenous; Subcutaneous, Liquid, Liquid - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intrathecal; Intravenous; Subcutaneous, Intrathecal, Injection, suspension, Injection, suspension - Intrathecal, Injection, solution - Intravenous, Intravenous, Injection, solution - Intravenous; Subcutaneous, Suspension, Suspension - Intrathecal, Injection, lipid complex, Injection, lipid complex - Intrathecal, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intrathecal; Intravenous; Subcutaneous, Powder, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder - Intravenous

Leukemia, Myelocytic, Acute

, 100.0 mg/mL, 20.0 mg/mL, 200.0 mg/mL, 100.0 mg, 500.0 mg, 2000.0 mg, 1000.0 mg, 50.0 mg, 50.0 mg/mL, 10.0 mg/mL, 5.0 mg/mL

, Injection, Injection - Intravenous; Subcutaneous, Intrathecal; Intravenous; Subcutaneous, Injection - Intrathecal; Intravenous; Subcutaneous, Intravenous; Subcutaneous, Powder, for solution, Powder, for solution - Intrathecal; Intravenous; Subcutaneous, Solution, Solution - Intrathecal; Intravenous; Subcutaneous, Liquid, Liquid - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intrathecal; Intravenous; Subcutaneous, Intrathecal, Injection, suspension, Injection, suspension - Intrathecal, Injection, solution - Intravenous, Intravenous, Injection, solution - Intravenous; Subcutaneous, Suspension, Suspension - Intrathecal, Injection, lipid complex, Injection, lipid complex - Intrathecal, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intrathecal; Intravenous; Subcutaneous, Powder, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder - Intravenous

Acute Myeloid Leukemia

, 100.0 mg/mL, 20.0 mg/mL, 200.0 mg/mL, 100.0 mg, 500.0 mg, 2000.0 mg, 1000.0 mg, 50.0 mg, 50.0 mg/mL, 10.0 mg/mL, 5.0 mg/mL

, Injection, Injection - Intravenous; Subcutaneous, Intrathecal; Intravenous; Subcutaneous, Injection - Intrathecal; Intravenous; Subcutaneous, Intravenous; Subcutaneous, Powder, for solution, Powder, for solution - Intrathecal; Intravenous; Subcutaneous, Solution, Solution - Intrathecal; Intravenous; Subcutaneous, Liquid, Liquid - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intrathecal; Intravenous; Subcutaneous, Intrathecal, Injection, suspension, Injection, suspension - Intrathecal, Injection, solution - Intravenous, Intravenous, Injection, solution - Intravenous; Subcutaneous, Suspension, Suspension - Intrathecal, Injection, lipid complex, Injection, lipid complex - Intrathecal, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intrathecal; Intravenous; Subcutaneous, Powder, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder - Intravenous

Warnings

There are 20 known major drug interactions with Depocyt.

Common Depocyt Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Cytarabine is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Cytarabine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abatacept

Major

The risk or severity of adverse effects can be increased when Cytarabine is combined with Abatacept.

Abetimus

Major

The risk or severity of adverse effects can be increased when Cytarabine is combined with Abetimus.

Acteoside

Major

The risk or severity of adverse effects can be increased when Cytarabine is combined with Acteoside.

Depocyt Toxicity & Overdose Risk

Overdosing on cytarabine can cause the "cytarabine syndrome," with symptoms such as fever, muscle pain, bone pain, chest pain, a rash, red eyes, and feeling unwell.

image of a doctor in a lab doing drug, clinical research

Depocyt Novel Uses: Which Conditions Have a Clinical Trial Featuring Depocyt?

621 active studies are currently being conducted to examine the potential of Depocyt for treating Acute Promyelocytic Leukemia, Leptomeningeal Metastases and prophylaxis against Meningeal leukemia.

Condition

Clinical Trials

Trial Phases

Acute Myeloid Leukemia

267 Actively Recruiting

Phase 2, Phase 3, Phase 1, Phase 4, Not Applicable, Early Phase 1

Non-Hodgkin's Lymphoma

115 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1, Phase 4

Acute Promyelocytic Leukemia

0 Actively Recruiting

Leukemia, Myelocytic, Acute

0 Actively Recruiting

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

0 Actively Recruiting

Newly Diagnosed

3 Actively Recruiting

Phase 3, Phase 1

Leukemia

0 Actively Recruiting

Neoplasm Metastasis

0 Actively Recruiting

Acute Lymphoblastic Leukemia

120 Actively Recruiting

Phase 1, Phase 2, Phase 3, Not Applicable, Early Phase 1, Phase 4

Leukemia, Myelocytic, Acute

0 Actively Recruiting

Leukemia

0 Actively Recruiting

Depocyt Reviews: What are patients saying about Depocyt?

5

Patient Review

1/8/2012

Depocyt for Lymphoma Spread to Brain & Spinal Cord Lining

I had ten treatments of Omya reservoir 4Tipotika in my lower spinal column. Afterward, my chronic fatigue syndrome was gone. I used to have migraines too, but they're also gone now. I'm very happy with the results!

5

Patient Review

7/17/2008

Depocyt for Lymphoma Spread to Brain & Spinal Cord Lining

After four doses of this treatment, I saw a total eradication of my lymphoma in the central nervous system. Unfortunately, it came back about nine months later. I went through a second round of treatment, this time biweekly for four sessions.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about depocyt

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is DepoCyt still available?

"Pacira Pharmaceuticals Inc. has discontinued DepoCyt, a treatment for lymphomatous meningitis, due to manufacturing challenges, the company announced Wednesday."

Answered by AI

What is the use of cytarabine injection?

"Cytarabine is used to treat certain types of leukemia, including acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and chronic myelogenous leukemia (CML). Cytarabine can be used alone or with other chemotherapy drugs."

Answered by AI

How is cytarabine liposomal administered?

"Liposomal cytarabine is given by intraventricular or intrathecal infusion in order to reach the cerebrospinal fluid surrounding the brain and spinal cord."

Answered by AI

What is cytarabine liposome injection?

"-DepoCyt is indicated for intrathecal treatment of lymphomatous meningitis -DepoCyt is a cytotoxic anticancer drug, handle with caution -Be sure to follow all handling instructions to prepare DepoCyt for administration"

Answered by AI

Clinical Trials for Depocyt

Image of National Institutes of Health Clinical Center in Bethesda, United States.

CD22 CAR T-cells for Acute Lymphoblastic Leukemia

3 - 65
All Sexes
Bethesda, MD

Background: Acute lymphoblastic leukemia (ALL) is a type of blood cancer. Chimeric antigen receptor (CAR) therapy involves taking immune cells (T cells) from a person and modifying them to better target cancer cells. CAR T-cell therapy that targets a marker called CD19 has been show to can cure ALL in many children and adults. But in about 50% of patients, the ALL comes back within a year. Researchers want to find out if a second treatment with CAR T-cell therapy that targets a different marker, CD22, can keep the cancer away longer. Objective: To see if CD22 CAR T-cell therapy can keep ALL away longer. Eligibility: People aged 3 to 65 years who have no signs of cancer after CD19 CAR T-cell treatment for ALL. Design: Participants will be screened. They will have imaging scans and tests of their heart function. A sample of tissue (biopsy) will be collected from their bone marrow. They will have a fluid sample collected from the area around their spinal cord. Participants will undergo collection of their white blood cells (T cells) during a procedure called leukapheresis. Blood will be taken from their body through a vein. The blood will pass through a machine that separates out the T cells. The remaining blood will be returned to the body through a different vein. The cells will be altered in a lab to create CD22 CAR T-cell therapy. Participants will take drugs over 4 consecutive days to prepare their body for the CAR T-cell therapy; then they will receive their modified T cells through a tube inserted into a vein. Some people may need to stay in the hospital during treatment. Participants will have follow-up visits for 2 years.

Phase 2
Waitlist Available

National Institutes of Health Clinical Center

Sara K Silbert, M.D.

Image of University of California Davis Comprehensive Cancer Center in Sacramento, United States.

Olutasidenib + Azacitidine for Acute Myeloid Leukemia

18+
All Sexes
Sacramento, CA

This phase II trial studies how well giving olutasidenib with azacitidine, followed by olutasidenib maintenance, works in treating patients with IDH1-mutated acute myeloid leukemia (AML) who have received prior treatment with venetoclax plus a hypomethylating agent (HMA-Ven). Olutasidenib and azacitidine may inhibit the growth of cancer cells by blocking certain enzymes required for cell growth. Maintenance therapy can help prevent or delay cancer from coming back. Olutasidenib with azacitidine followed by olutasidenib maintenance may be effective in treating patients with IDH1-mutated AML who have received prior HMA-Ven.

Phase 2
Recruiting

University of California Davis Comprehensive Cancer Center

Brian Jonas, MD

Have you considered Depocyt clinical trials?

We made a collection of clinical trials featuring Depocyt, we think they might fit your search criteria.
Go to Trials
Image of The University of Arizona Cancer Center in Tucson, United States.

DLI-X for Leukemia

Any Age
All Sexes
Tucson, AZ

The primary objective of this proposal is to conduct the first-in-human randomized clinical trial evaluating prophylactic DLI-X (pro-DLI-X) for relapse prevention following matched sibling donor (MSD) or haploidentical (haplo) hematopoietic cell transplantation (HCT) in patients with hematologic malignancies. Additionally, the study aims to assess the safety and efficacy of therapeutic DLI-X (t-DLI-X) compared to t-DLI alone in patients with minimal residual disease (MRD+) or overt relapse post-alloHCT. For patients with CD19-positive lymphoid malignancies, the study will incorporate blinatumomab, while those with myeloid or CD19-negative lymphoid malignancies will receive t-DLI-X or t-DLI alone. We hypothesize that both pro-DLI-X and t-DLI-X, with or without blinatumomab, will demonstrate safety and superior efficacy by enhancing graft-versus-leukemia (GvL) effects mediated by natural killer (NK) cells, γδ T cells, and CD8+ T cells, while maintaining manageable and treatment-responsive graft-versus-host disease (GvHD).

Phase 1
Waitlist Available

The University of Arizona Cancer Center

Emmanuel Katsanis, MD

Image of St. Jude Children's Research Hospital in Memphis, United States.

Tirzepatide + Resistance Exercise for Obesity in ALL Survivors

18+
All Sexes
Memphis, TN

This is a 28-week, single-arm, open-label phase II clinical trial evaluating the combination of Tirzepatide and remote, supervised, tailored resistance exercise training to achieve weight loss in adult survivors of childhood acute lymphoblastic leukemia (ALL) living with obesity or overweight with comorbidity. Primary Objective(s): • To evaluate the effectiveness for weight loss of the combined intervention using once weekly Tirzepatide plus remote, supervised, tailored resistance exercise (three sessions per week) in adult survivors of childhood ALL with obesity or overweight (BMI ≥27 kg/m2) with ≥1 weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). The effectiveness will be estimated as the proportion of evaluable participants who achieve at least 5% weight loss from baseline to week 28. The study will target a proportion of participants achieving 5% weight loss of 70% and consider fewer than 40% achieving 5% weight loss as unacceptable. Secondary Objective(s): * Estimate the proportion of participants who adhere to the 28-week combined intervention. Adherence to Tirzepatide will be defined as receiving at least 70% of prescribed doses. Adherence to resistance exercise will be defined as attending at least 50% of prescribed exercise sessions. Adherence to the combined intervention will be considered if participants complete the study and meet both the Tirzepatide and exercise adherence endpoint. The adherence to each component of the intervention will also be reported. * Estimate the average percentage weight loss from week 0 to 28 for participants completing the combined 28-week intervention. The study will target a mean weight reduction of 10% and consider \<5% unacceptable.

Phase 2
Waitlist Available

St. Jude Children's Research Hospital

Stephanie B Dixon, MD, MPH

Image of OHSU Knight Cancer Institute in Portland, United States.

Fludarabine + Cytarabine + Idarubicin + Venetoclax for Acute Myeloid Leukemia

18 - 65
All Sexes
Portland, OR

This phase II trial compares induction and consolidation therapy with fludarabine, cytarabine, idarubicin, and venetoclax to cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of acute myeloid leukemia (AML). Patients with AML often receive induction and consolidation therapy. Induction therapy is given first to get the patient's AML under control (remission). Consolidation therapy is given after the cancer has disappeared following the initial therapy. Consolidation therapy is used to kill any cancer cells that may be left in the body. Chemotherapy drugs, such as fludarabine, cytarabine, idarubicin, and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving fludarabine, cytarabine, idarubicin, and venetoclax for induction and consolidation therapy may be more effective in treating AML.

Phase 2
Waitlist Available

OHSU Knight Cancer Institute

Curtis A Lachowiez

Have you considered Depocyt clinical trials?

We made a collection of clinical trials featuring Depocyt, we think they might fit your search criteria.
Go to Trials
Image of University of California, San Diego in La Jolla, United States.

SB-4826 for Non-Hodgkin's Lymphoma

18+
All Sexes
La Jolla, CA

The goal of this clinical trial is to learn what dose of the drug SB-4826 can be given safely in patients with solid tumors and non-Hodgkin lymphomas. This drug will be used alone in patients with solid tumors, and will be used alone or in combination with rituximab in patients with non-Hodgkin lymphomas. The main questions this clinical trial aims to answer are: What is the maximum dose of SB-4826 that can be used safely in patients with solid tumors and non-Hodgkin lymphomas, and will it work? How does SB-4826 work in people with cancer? How is SB-4826 absorbed, broken down, and excreted by the body? Participants will: Take drug SB-4826 every other day for up to 1 year; keep a diary of when they take SB-4826 at home; visit the clinic for checkups, tests, and fill out study questionnaires.

Phase 1 & 2
Waitlist Available

University of California, San Diego

Peter Vu, MD

Have you considered Depocyt clinical trials?

We made a collection of clinical trials featuring Depocyt, we think they might fit your search criteria.
Go to Trials